Federico Ferraro

Mr. Federico Ferraro

Erasmus MC
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2021 in Parkinsonism & Related Disorders
Verified
Journal Article
Open access
AFAkrivi Christina Fevga
Akrivi Christina Fevga
YPYangshin Park
Yangshin Park
ELEbba Lohmann
Ebba Lohmann
AKAnneke J. Kievit
Anneke J. Kievit
GBGuido J. Breedveld
Guido J. Breedveld
Vincenzo BonifatiVincenzo Bonifati
Vincenzo Bonifati
Missense variants and multiplications of the alpha-synuclein gene (SNCA) are established as rare causes of autosomal dominant forms of Parkinson's Disease (PD). Two families of Turkish origins with PD were studied; the SNCA coding region was analyzed by Sanger sequencing, and by whole exome sequencing (WES) in the index patient of the first and the second family, respectively. Co-segregation studies and haplotype analysis across the SNCA locus were carried out. Functional studies included in vitro thioflavin-T aggregation assay and in silico structural modelling of the alpha-synuclein (α-syn) protein. We identified a novel heterozygous SNCA variant, c.215C > T (p.Thr72Met), segregating with PD in a total of four members in the two families. A shared haplotype across the SNCA locus was found among variant carriers, suggestive of a common ancestor. We next showed that the Thr72Met α-syn displays enhanced aggregation in-vitro, compared to the wild-type species. In silico analysis of a tetrameric α-syn structural model revealed that Threonine 72 lies in the tetrameric interface, and substitution with the much larger methionine residue could potentially destabilize the tetramer. We present clinical, genetic, and functional data supporting a causative role of the SNCA c.215C > T (p.Thr72Met) variant in familial PD. Testing for this variant in patients with PD, especially of Turkish origin, might detect additional carriers. Further functional analyses might offer new insights into the shared biochemical properties of the PD-causing SNCA missense variants, and how they lead to neurodegeneration.

Verified
Journal Article
Open access
PDF file
LPLaura Pulze
Laura Pulze
TCTerenzio Congiu
Terenzio Congiu
TBTiziana A.L. Brevini
Tiziana A.L. Brevini
Annalisa GrimaldiAnnalisa Grimaldi
Annalisa Grimaldi
Gianluca TettamantiGianluca Tettamanti
Gianluca Tettamanti
MEMagda Anna de Eguileor
Magda Anna de Eguileor
Human breast adenocarcinoma cells (MCF7) grow in three-dimensional culture as spheroids that represent the structural complexity of avascular tumors. Therefore, spheroids offer a powerful tool for studying cancer development, aggressiveness, and drug resistance. Notwithstanding the large amount of data regarding the formation of MCF7 spheroids, a detailed description of the morpho-functional changes during their aggregation and maturation is still lacking. In this study, in addition to the already established role of gap junctions, we show evidence of tunneling nanotube (TNT) formation, amyloid fibril production, and opening of large stable cellular bridges, thus reporting the sequential events leading to MCF7 spheroid formation. The variation in cell phenotypes, sustained by dynamic expression of multiple proteins, leads to complex networking among cells similar to the sequence of morphogenetic steps occurring in embryogenesis/organogenesis. On the basis of the observation that early events in spheroid formation are strictly linked to the redox homeostasis, which in turn regulate amyloidogenesis, we show that the administration of N-acetyl-l-cysteine (NAC), a reactive oxygen species (ROS) scavenger that reduces the capability of cells to produce amyloid fibrils, significantly affects their ability to aggregate. Moreover, cells aggregation events, which exploit the intrinsic adhesiveness of amyloid fibrils, significantly decrease following the administration during the early aggregation phase of neutral endopeptidase (NEP), an amyloid degrading enzyme.

8 September 2022 in Brain
Verified
Journal Article
Open access
PDF file
AFAkrivi Christina Fevga
Akrivi Christina Fevga
CTChristelle Tesson
Christelle Tesson
AMAna Carreras Mascaro
Ana Carreras Mascaro
TCThomas Courtin
Thomas Courtin
RCRiaan van Coller
Riaan van Coller
Vincenzo BonifatiVincenzo Bonifati
Vincenzo Bonifati
The protein phosphatase 2A complex (PP2A), the major Ser/Thr phosphatase in the brain, is involved in a number of signalling pathways and functions, including the regulation of crucial proteins for neurodegeneration, such as alpha-synuclein, tau and LRRK2. Here, we report the identification of variants in the PTPA/PPP2R4 gene, encoding a major PP2A activator, in two families with early-onset parkinsonism and intellectual disability. We carried out clinical studies and genetic analyses, including genome-wide linkage analysis, whole-exome sequencing, and Sanger sequencing of candidate variants. We next performed functional studies on the disease-associated variants in cultured cells and knock-down of ptpa in Drosophila melanogaster. We first identified a homozygous PTPA variant, c.893T>G (p.Met298Arg), in patients from a South African family with early-onset parkinsonism and intellectual disability. Screening of a large series of additional families yielded a second homozygous variant, c.512C>A (p.Ala171Asp), in a Libyan family with a similar phenotype. Both variants co-segregate with disease in the respective families. The affected subjects display juvenile-onset parkinsonism and intellectual disability. The motor symptoms were responsive to treatment with levodopa and deep brain stimulation of the subthalamic nucleus. In overexpression studies, both the PTPA p.Ala171Asp and p.Met298Arg variants were associated with decreased PTPA RNA stability and decreased PTPA protein levels; the p.Ala171Asp variant additionally displayed decreased PTPA protein stability. Crucially, expression of both variants was associated with decreased PP2A complex levels and impaired PP2A phosphatase activation. PTPA orthologue knock-down in Drosophila neurons induced a significant impairment of locomotion in the climbing test. This defect was age-dependent and fully reversed by L-DOPA treatment. We conclude that bi-allelic missense PTPA variants associated with impaired activation of the PP2A phosphatase cause autosomal recessive early-onset parkinsonism with intellectual disability. Our findings might also provide new insights for understanding the role of the PP2A complex in the pathogenesis of more common forms of neurodegeneration.

11 June 2024 in Clinical Genetics
Verified
Journal Article
Open access
RSRachel Schot
Rachel Schot
FFFederico Ferraro
Federico Ferraro
GGGeert Geeven
Geert Geeven
KDKarin E. M. Diderich
Karin E. M. Diderich
TBTahsin Stefan Barakat
Tahsin Stefan Barakat
Despite increasing knowledge of disease‐causing genes in human genetics, approximately half of the individuals affected by neurodevelopmental disorders remain genetically undiagnosed. Part of this missing heritability might be caused by genetic variants outside of protein‐coding genes, which are not routinely diagnostically investigated. A recent preprint identified de novo variants in the non‐coding spliceosomal snRNA gene RNU4‐2 as a cause of a frequent novel syndromic neurodevelopmental disorder. Here we mined 164 whole genome sequencing (WGS) trios from individuals with neurodevelopmental or multiple congenital anomaly disorders that received diagnostic genomic investigations at our clinic. We identify a recurrent de novo RNU4‐2 variant (NR_003137.2(RNU4‐2):n.64_65insT) in a 5‐year‐old girl with severe global developmental delay, hypotonia, microcephaly, and seizures that likely explains her phenotype, given that extensive previous genetic investigations failed to identify an alternative cause. We present detailed phenotyping of the individual obtained during a 5‐year follow‐up. This includes photographs showing recognizable facial features for this novel disorder, which might allow prioritizing other currently unexplained affected individuals sharing similar facial features for targeted investigations of RNU4‐2. This case illustrates the power of re‐analysis to solve previously unexplained cases even when a diagnostic genome remains negative.

29 July 2025 in European Journal of Human Genetics
Verified
Journal Article
Closed access
DSDaphne J. Smits
Daphne J. Smits
CDChristophe Debuy
Christophe Debuy
ABAlice S. Brooks
Alice S. Brooks
RSRachel Schot
Rachel Schot
FFFederico Ferraro
Federico Ferraro
TBTahsin Stefan Barakat
Tahsin Stefan Barakat

20 October 2025 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
DSDaphne J. Smits
Daphne J. Smits
FFFederico Ferraro
Federico Ferraro
MDMark Drost
Mark Drost
HLHerma C. van der Linde
Herma C. van der Linde
BGBianca M. de Graaf
Bianca M. de Graaf
VVVirginie J. M. Verhoeven
Virginie J. M. Verhoeven
Critically ill pediatric patients often have genetic disorders requiring a rapid diagnosis to guide urgent care decisions. Standard genetic testing typically takes weeks and requires multiple tests. Nanopore long-read genome sequencing (LR-GS) delivers genome-wide results within days as a one-test-fits-all solution. As one of the first centers in Europe, we implement ultrarapid LR-GS for critically ill patients. We enrolled 26 critically ill patients (median age 2 months) suspected of having a genetic disorder at the intensive care unit to perform (ultra)rapid nanopore LR-GS alongside standard genomic care. We compared diagnostic yield, turnaround time (TAT), and evaluated the impact on clinical decision making. In 11/26 cases a genetic diagnosis was made with (ultra)rapid LR-GS. From sample receipt to result, the average TAT was 5.3 days (range 2.0–10.8) for LR-GS and 18.4 days (range 6.1–29.1) for standard genomic care. DNA methylation analysis from LR-GS expedited the diagnosis in 3/26 cases. In 7/11 solved cases ultrarapid LR-GS led to immediate adjustments in patient care, e.g., medication switch or termination of treatment. Our findings underscore the clinical impact of ultrarapid LR-GS, including added value of methylation analysis, for critically ill patients and highlight existing challenges, paving the way to ultrarapid LR-GS integration into standard diagnostics.